RE:RE:RE:RE:RE:RE:RE:Going Nowhere at accelerating rateWhen facts are against you change the narrative. Not voting does not mean support. Then there is “Et Tu Brutus” Than there is voting with the share price. Facts GUD in six Years has not being able to provide a reasonable rate of returns on their equity. They have a lot of catch up to do but there is no huge potential insight that will be able to do that soon if at all. Licensing strategies are no longer available with globalizations and new biotech start risk shared strategies, unless a company’s takes the risk and participates in late trial development strategies, they will not get a chance to participate in profits. Simply look at Pfizer, Sanofi, AstraZeneca and other ones. In the last months they paid billions to participate for covid-10 vaccines. Local nations Carpet beggars’ new drugs licensing strategies no longer works like in past Paladin days. Sadly, GUD along with a high profile and respected CEO has proven in six Years of trying and with lots of cash to booth that the strategy no longer works. The way I understand it, though I admit I could be wrong, now GUD is pursuing after marked re-branded drugs in South America. Here is the problem in S America demographics, those who can afford new developed drugs they will travel anywhere to get it. Those who cannot afford new drugs will only pay and get cheap low margin drugs. I will be happy to be proven wrong by facts and not bs talk.